Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Anti-aromatase agents are used to support the estrogen body system primarily due to substantial scientific evidence. Aromatase is an enzyme responsible for the conversion of androgens (such as testosterone) to estrogens (such as estradiol) in the body. In certain clinical contexts, such as estrogen receptor-positive breast cancer, anti-aromatase drugs (commonly called aromatase inhibitors) are prescribed to lower estrogen levels, thereby slowing or preventing tumor growth that depends on estrogen. Examples of these pharmaceuticals include anastrozole, letrozole, and exemestane.

In addition to oncology, anti-aromatase agents are sometimes investigated for male hypogonadism, gynecomastia, and infertility, where excess estrogen is implicated. They are also of interest in the context of bodybuilding and hormone therapy, where they may be used off-label to prevent estrogenic side effects of anabolic steroid use.

There is robust clinical trial and mechanistic evidence supporting the efficacy of anti-aromatase medications in lowering estrogen levels. However, their use outside of well-defined clinical indications should be approached with caution due to potential side effects, including bone loss, lipid changes, and musculoskeletal symptoms. In summary, anti-aromatase agents are scientifically validated for the modulation of the estrogen system, particularly in specific medical indications.

More about anti-aromatase
More about Estrogen

Other ingredients that support Estrogen

Other body systems supported by anti-aromatase

Products containing anti-aromatase